Los Angeles Biomedical Research Institute at Harbor-ucla Medical Center

Brad J Spellberg

Ashraf S Ibrahim

John E Edwards, Jr

Yue Fu

Scott G Filler

Guanpingsheng Luo

Lin Lin

Michael R Yeaman

Donald Christopher Sheppard

Mingfu Liu

Kevin W Bruhn

Travis Nielsen

John E Edwards

Presented herein, in certain embodiments, are compositions comprising antibody binding agents that specifically bind toand inhibit and/or blockinfection, and uses thereof.

Antibody binding agents that bindand uses thereof

Abloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Pharmaceutical compositions and methods to vaccinate against candidiasis

The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.

Mammalian receptors as targets for antibody and active vaccination therapy against mold infections

The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial inventions. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-&#x3b2;-lactamase or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for treating and preventing a bacterial infection using the vaccine and pharmaceutical compositions of the invention. The invention further provides antibody conjugates that include an antibody or fragment thereof conjugated to a siderophore or an analog thereof.

Compositions and methods for immunization against bacteria expressing a carbapenemase

The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.

Methods for treating refractory infections in neutropenic individuals

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization againstinfection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization againstinfection. The compositions and methods of the invention are useful for preventing or treatinginfections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR)infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR)infections.

[object Object]

The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.

The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

Growing community of inventors

Rancho Palos Verdes, CA, United States of America

Brad J Spellberg